AtheroGenics, Inc.

Not before time last week, the SEC fired a shot across the bows of pharmaceutical and biotechnology companies that have been failing to accurately portray their dealings with the FDA. At the Annual Ph

The Private Securities Litigation Reform Act of 1995, or Forward-Looking Statement Safe Harbor disclaimer as it is better known, advises investors that under such a disclaimer, companies can make fina

Cerenis Therapeutics (France/US), a privately held pharmaceutical company developing novel HDL therapies to treat cardiovascular and other metabolic diseases, has made the following appointments: Tom

Most biotechs and their investors prefer exit-by-acquisition; Infinity is opting to stay quasi-single with the first real attempt to replicate the Roche/Genentech dependent independence model. But the